Accueil   Diary - News   All news Poxel Announces Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes

Poxel Announces Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes

 

 

 

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced with its partner, Sumitomo Dainippon Pharma, that the product launch of TWYMEEG®1 (Imeglimin hydrochloride), 500mg tablets for the treatment of type 2 diabetes in Japan, is planned for September 16, 2021. 

 

 

Read the press release